Study explores effect of hereditary cancer risk assessments on families of patients with prostate cancer

“This is one of the first large-scale, and by that, I mean a national-based study throughout the United States, with geographical diversity of community-based urology practices that had a pretty sophisticated background of advanced prostate cancer care,” says Neal D. Shore, MD, FACS.

In this video, Neal D. Shore, MD, FACS, discusses the background and methods of the study, “Hereditary cancer risk assessment in the community urology practice setting,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.